⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30549335 | 0.97 | — | — | |
| SCHEMBL31474437 | 0.97 | — | — | |
| SCHEMBL1177955 | 0.67 | — | — | |
| SCHEMBL27943491 | 0.63 | — | — | |
| SCHEMBL3751577 | 0.63 | — | — | |
| SCHEMBL28372254 | 0.63 | RECQL (0.39) | — | |
| SCHEMBL277059 | 0.62 | — | — | |
| SCHEMBL688972 | 0.62 | — | — | |
| SCHEMBL11409247 | 0.62 | — | — | |
| SCHEMBL9396453 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 552 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241965-A1 | METHOD TO IMPROVE CELL VIABILITY OF CARDIOMYOCYTES | UNIVERSITY OF WASHINGTON (US) | 2025-07-31 | — | — | US | claimed |
| US-20250179429-A1 | CELL CULTURE MEDIUM | UPSIDE BIOTECHNOLOGIES LIMITED (NZ) | 2025-06-05 | — | — | US | claimed |
| EP-4504909-A1 | METHOD TO IMPROVE CELL VIABILITY OF CARDIOMYOCYTES | University of Washington (US) | 2025-02-12 | — | — | EP | claimed |
| CN-111148829-B | Cell culture medium | 奥克兰联合服务有限公司 | 2025-02-11 | — | — | CN | claimed |
| CN-117586246-B | NO donor coumarin Mannich base compound and preparation method and application thereof | 安徽中医药大学 | 2025-01-14 | — | — | CN | claimed |
| US-20240423997-A1 | METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | WOOLSEY PHARMACEUTICALS, INC. | 2024-12-26 | — | — | US | claimed |
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-21 | — | — | US | claimed |
| CN-116143720-B | Energetic material bis (4-nitro-1, 2, 5-oxadiazole-3-yl) amine and preparation method thereof | 中国工程物理研究院化工材料研究所 | 2024-05-14 | — | — | CN | claimed |
| CN-117603200-A | Preparation method of nitrofurazan compound | 中国工程物理研究院化工材料研究所 | 2024-02-27 | — | — | CN | claimed |
| CN-117586246-A | NO donor coumarin Mannich base compound and preparation method and application thereof | 安徽中医药大学 | 2024-02-23 | — | — | CN | claimed |
| CN-1133626-C | Diclofenac coupled derivative and its synthesizing process and inflammation relieving action | 南京长澳医药科技有限公司 | 2004-01-07 | — | — | CN | claimed |
| CN-1305997-A | Diclofenac coupled derivative and its synthesizing process and inflammation relieving action | CHINESE PHARMACY UNIV (CN) | 2001-08-01 | — | — | CN | claimed |
| US-5352688-A | Methods for the treatment of bradyphrenia in parkinson's disease | THE MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK (US) | 1994-10-04 | — | — | US | claimed |
| EP-0253175-B1 | SUBSTITUTED FURAZANS | BAYER AG (DE) | 1992-12-30 | — | — | EP | claimed |
| US-5070101-A | Method and pharmaceutical composition for the treatment of schizophrenia | MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK (US) | 1991-12-03 | — | — | US | claimed |
| EP-0189043-B1 | SUBSITUED FURAZANS | BAYER AG (DE) | 1989-03-08 | — | — | EP | claimed |
| EP-0253175-A2 | Substituted furazans | BAYER AG (DE) | 1988-01-20 | — | — | EP | claimed |
| EP-0132680-B1 | SUBSTITUTED FURAZANS | BAYER AG (DE) | 1987-01-28 | — | — | EP | claimed |
| EP-0189043-A1 | Subsitued furazans | BAYER AG (DE) | 1986-07-30 | — | — | EP | claimed |
| EP-0132680-A1 | Substituted furazans | BAYER AG (DE) | 1985-02-13 | — | — | EP | claimed |